# Islatravir + Lenacapavir: First Once-Weekly Oral HIV Treatment

**ID:** TRT-006
**Year:** 2024
**Sponsors:** Gilead Sciences, Merck
**Conference:** ID Week 2024, CROI 2024
**Phase 3 Trials:** NCT06629286, NCT06629299 (ISLEND-1, ISLEND-2)

---

## Abstract

The combination of islatravir and lenacapavir represents a potential paradigm shift in HIV treatment—the first once-weekly oral regimen. Phase 2 data showed 94.2% viral suppression maintained at 48 weeks, comparable to daily Biktarvy, with the transformative convenience of weekly dosing. Phase 3 trials are now recruiting.

---

## Key Concepts

- **Islatravir**: First nucleoside reverse transcriptase translocation inhibitor (NRTtI)
- **Lenacapavir**: First-in-class HIV-1 capsid inhibitor
- **Once-weekly dosing**: Enabled by long half-lives of both drugs
- **Dual mechanism**: Two novel targets in a single regimen

---

## Drug Profiles

### Islatravir (MK-8591)
| Property | Details |
|:---------|:--------|
| Class | NRTtI (new class) |
| Developer | Merck |
| Mechanism | Inhibits reverse transcriptase translocation |
| Half-life | Long (enables weekly dosing) |
| Unique feature | Active against NRTI-resistant virus |

### Lenacapavir (GS-6207)
| Property | Details |
|:---------|:--------|
| Class | Capsid inhibitor (first-in-class) |
| Developer | Gilead Sciences |
| Mechanism | Disrupts capsid functions at multiple stages |
| Half-life | Extremely long |
| Unique feature | Active against multi-drug resistant HIV |

---

## Phase 2 Clinical Trial Results

### Week 24 Results (CROI 2024)
| Arm | N | Viral Suppression |
|:----|:--|:------------------|
| Islatravir + Lenacapavir (weekly) | 52 | **94.2%** |
| Biktarvy (daily) | 52 | 94.2% |

### Week 48 Results (ID Week 2024)
| Arm | N | Viral Suppression | VL ≥50 copies/mL |
|:----|:--|:------------------|:-----------------|
| Islatravir + Lenacapavir | 52 | **94.2%** | **0 (0%)** |
| Biktarvy | 52 | 92.3% | 2 (3.8%) |

### Key Finding
> "Zero participants had a viral load of ≥50 copies/mL at Week 48" in the islatravir + lenacapavir arm.

---

## Safety Profile

### Treatment-Related Adverse Events (Week 48)
| Arm | Any TRAE | Most Common |
|:----|:---------|:------------|
| ISL + LEN | 19.2% | Dry mouth (3.8%), nausea (3.8%) |
| Biktarvy | 5.8% | — |

### CD4 and Lymphocyte Counts
| Finding | Result |
|:--------|:-------|
| CD4 changes | No significant difference between arms |
| Lymphocyte changes | Stable in both arms |
| Discontinuations for CD4 decline | None |

---

## Phase 3 Development

### ISLEND Studies (Recruiting)
| Trial | Design | Comparator |
|:------|:-------|:-----------|
| ISLEND-1 | Switch study | B/F/TAF (Biktarvy) |
| ISLEND-2 | Switch study | Existing guideline regimens |

### Fixed-Dose Combination
- **Formulation**: ISL 2 mg + LEN 300 mg once weekly
- **Regulatory status**: Investigational (not yet approved)

---

## Significance

### Treatment Paradigm Shift
1. **First weekly oral HIV treatment** if approved
2. **Reduces pill burden** from 365 to 52 doses/year
3. **Novel mechanisms** active against resistant virus
4. **Patient preference** for less frequent dosing

### Comparison of Dosing Frequencies
| Regimen | Frequency | Doses/Year |
|:--------|:----------|:-----------|
| Traditional ART | Daily | 365 |
| **ISL + LEN** | **Weekly** | **52** |
| Cabenuva | Monthly | 12 |
| Lenacapavir alone | Twice yearly | 2 |

---

## Relevance to Project

This novel combination informs the Ternary VAE project:
- **Capsid sequences**: Critical target for lenacapavir
- **RT sequences**: Novel mechanism of islatravir action
- **Resistance barriers**: Two high-barrier agents combined
- **Codon constraints**: Understanding multiple drug target sites

---

*Added: 2025-12-24*
